-
The effects of coffee on the heart remain incompletely described. There are conflicting reports of coffee's effects on the incidence of coronary artery disease, heart failure (HF), atrial fibrillation, and glucose homeostasis.
-
Many clinical trials have confirmed the benefit of early invasive therapy for high-risk patients presenting with acute coronary syndromes (ACS). However, the optimal timing of cardiac catheterization in this group remains unknown.
-
Depression and pregnancy, new vaccine recommendations from the CDC, cortico-steroids and/or antivirals for Bell's palsy, rasagiline and Parkinson's disease, and FDA Actions.
-
-
Erratic intraindividual INR values on chronic warfarin therapy are thought to be due to variability in vitamin K intake in the diet. Thus, de Assis et al from Brazil hypothesized that a dietary, vitamin K management strategy would result in improved long-term anticoagulation as compared to traditional systems based upon drug-dose adjustments alone.
-
Dabigatran etexilate is an oral compound that is converted after absorption by a serum esterase to dabigatran, a direct competitive inhibitor of thrombin.
-
Current indications for cardiac-resynchronization therapy (CRT) require that patients have New York Heart Association (NYHA) Class III or Class IV heart-failure symptoms. However, long-standing ventricular dyssynchrony can lead to left-ventricular remodeling and decreased left-ventricular ejection fraction.
-
The timing of mitral valve surgery in patients with severe organic mitral regurgitation (MR), but without symptoms, is controversial.
-
Concerns about the potential increased risk of prostate cancer associated with high intakes of alpha-linolenic acid (ALA; 18:3n-3) were re-assessed by the authors of this systematic review, but the aforementioned concerns could not be completely allayed.
-
There is no agreed upon standard therapy for men experiencing inflammatory chronic prostatitis/ chronic pelvic pain syndrome (CP/CPPS). The results of this strong clinical trial suggest that a 12-week course of therapy with a specific pollen extract is significantly more effective than placebo in reducing the symptoms of CP/CPPS, especially pain.